Publications

September 2024
Article

Comprehensive Measurement of Biopharmaceutical R&D Investment

By: Amitabh Chandra, John Drum, Michael Daly, Henry Mirsberger, Samuel Spare, Ulrich Neumann, Silas Martin and Noam Kirson

Keywords: Research and Development; Investment; Pharmaceutical Industry

January 2022 (Revised July 2022)
Case

Gilead Sciences: Developing a Biopharmaceutical Pipeline Through M&A

By: Amitabh Chandra, Paul Clancy and Craig Garthwaite

July 2022
Teaching Note

Gilead Sciences: Developing a Biopharmaceutical Pipeline Through M&A

By: Amitabh Chandra, Paul Clancy and Craig Garthwaite

Teaching Note for HBS Case No. 622-075. View Details

July 2022
Supplement

Gilead Sciences: Developing a Biopharmaceutical Pipeline Through M&A (Spreadsheet Supplement)

By: Amitabh Chandra, Paul Clancy and Craig Garthwaite

Spring 2014
Article

Attracting Long-Term Investors Through Integrated Thinking and Reporting: A Clinical Study of a Biopharmaceutical Company

By: Andrew Knauer and George Serafeim

Faced with a large percentage of investors that chase short-term returns, companies could benefit by attracting investors with longer-term horizons and incentives that are more consistent with the long-term strategy of the company. The managers of most companies take... View Details

Keywords: Investing; Asset Management; Long-term Investing; Short-termism; Sustainability; Integrated Reporting; Leadership & Corporate Accountability; Pharmaceuticals; Leadership; Integrated Corporate Reporting; Investment; Business and Stakeholder Relations; Corporate Finance; Biotechnology Industry; Pharmaceutical Industry

Find at Harvard

2000
Chapter

In Search of Dynamic Capabilities: The Origins of R&D Competence in Biopharmaceuticals

By: Gary P. Pisano

Keywords: Competency and Skills; Research and Development; Pharmaceutical Industry; Biotechnology Industry

Find at Harvard

01 Mar 2007
News

Pharma Suits a Farm Gal

GRAHAM: From rodeo to CEO. Amylin Pharmaceuticals CEO Ginger Graham (MBA ’86) had a good year in 2006, with Amylin stock up as much as 45 percent, with Byetta and Symlin, its two innovative diabetes drugs, performing well, and with the company added to the Nasdaq 100.... View Details

Keywords: biopharmaceutical company; Health, Social Assistance; Corporate, Subsidiary, and Regional Managing Offices; Management

April 2023
Case

Elliott Management: Capital Allocation in Biopharma

By: Amitabh Chandra, Paul Clancy and Lauren Gunasti

The case explores the intersection of capital allocation and shareholder activism in the biopharmaceutical industry. As many biopharma companies face looming patent expirations for key medicines, the case asks the question of whether investing in R&D and M&A is an... View Details

Keywords: Finance; Strategy; Capital Allocation; Biopharmaceutical Industry; Shareholder Activism; Investment Activism; Resource Allocation; Research and Development; Business and Shareholder Relations; Corporate Strategy; Pharmaceutical Industry

01 Dec 2013
News

Your Own Medicine

WILLIAMS CHARLEY SECKLER in the midst of the first-ever trial for a DMD treatment at Johns Hopkins University. Photo courtesy the Seckler Family by Dan Morrell There's this picture of Charley Seckler from last summer that his mom has sent to everyone: Her 12-year-old... View Details

Keywords: Morrell, Daniel; biomedicine; biopharmaceutical company; Ambulatory Health Care Services; Health, Social Assistance

September 2022
Article

Find and Replace: R&D Investment Following the Erosion of Existing Products

By: Joshua L. Krieger, Xuelin Li and Richard T. Thakor

How do innovative firms react when existing products experience negative shocks? We explore this question with detailed project-level data from drug development firms. Using FDA Public Health Advisories as idiosyncratic negative shocks to approved drugs, we first... View Details

Keywords: R＆D Investments; Drug Development; Product Shocks; M＆A; Biopharmaceutical Industry; FDA; System Shocks; Research and Development; Investment; Decision Making; Pharmaceutical Industry

12 Nov 2019
Video

Kiran Mazumdar-Shaw

Kiran Mazumdar-Shaw, Chairperson and Managing Director of Biocon, India’s largest biopharmaceutical company, relates how gender bias set her on a path to invest in industrial enzymes and the foundation of... View Details

Video

Yaso Biotechnology Inc. - 2013 HBS Alumni New Venture Competition Social Enterprise Track Winner

May 1998 (Revised May 1999)
Case

Biopure Corp.

By: John T. Gourville

It is early 1998 and Biopure Corp., a small biopharmaceutical firm with no sales revenues in its ten-year history, has just received government approval to release Oxyglobin, a revolutionary new "blood substitute" designed to replace the need for donated animal blood... View Details

Keywords: Segmentation; Marketing Strategy; Engineering; Budgets and Budgeting; Sales; Transformation; Markets; Debates; Product Launch; Pharmaceutical Industry

12 Nov 2019
Video

Kiran Mazumdar Shaw

Kiran Mazumdar-Shaw, Chairperson and Managing Director of Biocon, India’s largest biopharmaceutical company, explains how her firm developed over four years a new technology for making insulin, an essential... View Details

12 Nov 2019
Video

Kiran Mazumdar-Shaw

Kiran Mazumdar-Shaw, Chairperson and Managing Director of Biocon, India’s largest biopharmaceutical company, discusses how the firm has been able to create a world class innovation center in Bangalore despite... View Details

12 Nov 2019
Video

Kiran Mazumdar Shaw

Kiran Mazumdar-Shaw, Chairperson and Managing Director of Biocon, India’s largest biopharmaceutical company, discusses how partnerships with Unilever, Cuban research institutes, and the global health companies... View Details

12 Nov 2019
Video

Kiran Mazumdar-Shaw

Kiran Mazumdar-Shaw, Chairperson and Managing Director of Biocon, India’s largest biopharmaceutical company, discusses her ambition to promote women’s careers, noting that although 30 per cent of company... View Details

January 2005 (Revised March 2006)
Case

Molecular Insight Pharmaceuticals, Inc.

By: Richard G. Hamermesh and Edwin W. Parkinson III

Molecular Insight has developed a novel biopharmaceutical to detect heart attacks. The company's unique approach to intellectual property protection uses the Hatch Waxman Act and the Orphan Drug Act. The company is struggling to raise $7 million in Series B financing.... View Details

Keywords: Intellectual Property; Health Care and Treatment; Pharmaceutical Industry; Health Industry

January 2018
Supplement

BeiGene Supplemental PowerPoint

By: Willy C. Shih and Jimmy Zhang

BeiGene was a biopharmaceutical company founded on exploiting a temporal regulatory policy discontinuity. Because of regulatory challenges in China, most innovative new drugs launched there four to six years after their initial U.S. launches. This gave BeiGene a window... View Details

Keywords: Biotechnology; Pharmaceutical Company; Pharmaceuticals; China; Regulatory Environment; Business Strategy; Innovation Strategy; Situation or Environment; Pharmaceutical Industry; Biotechnology Industry; China